Pten and p53 Loss in the Mouse Lung Causes Adenocarcinoma and Sarcomatoid Carcinoma

• Published in: Cancers Vol. 14; no. 15; p. 3671
• Main Authors: Lázaro, Sara, Lorz, Corina, Enguita, Ana Belén, Seller, Iván, Paramio, Jesús M., Santos, Mirentxu
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 28.07.2022; MDPI
• Subjects: Adenocarcinoma; Adenoviruses; Animal models; Cancer therapies; Cell cycle; Kinases; Latency; lung adenocarcinoma; Lung cancer; Lung carcinoma; Medical prognosis; Mutation; Naphthalene; Non-small cell lung carcinoma; p53; p53 Protein; Patients; PTEN; PTEN protein; pulmonary sarcomatoid carcinoma; Senescence; Transcriptomics; Tumor suppressor genes; Tumors
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14153671

Lung cancer remains the leading cause of cancer deaths worldwide. Among the Non-Small Cell Carcinoma (NSCLC) category, Adenocarcinoma (ADC) represents the most common type, with different reported driver mutations, a bunch of models described and therapeutic options. Meanwhile, Pulmonary Sarcomatoid Carcinoma (PSC) is one of the rarest, with very poor outcomes, scarce availability of patient material, no effective therapies and no models available for preclinical research. Here, we describe that the combined deletion of Pten and Trp53 in the lungs of adult conditional mice leads to the development of both ADC and PSC irrespective of the lung targeted cell type after naphthalene induced airway epithelial regeneration. Although this model shows long latency periods and incomplete penetrance for tumor development, it is the first PSC mouse model reported so far, and sheds light on the relationships between ADC and PSC and their cells of origin. Moreover, human ADC show strong transcriptomic similarities to the mouse PSC, providing a link between both tumor types and the human ADC.